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Abstract 
Entry inhibitors are emerging as an attractive class of therapeutics for hepatitis C virus 
(HCV) infection. Entry inhibitors target either virion-associated factors or cellular factors 
necessary for infection. By blocking entry into cells, entry inhibitors prevent both the 
establishment of persistent reservoirs and the emergence of resistant variants during viral 
replication. Furthermore, entry inhibitors protect naïve cells from virus-induced 
alterations. Combining entry inhibitors with direct acting antivirals (DAAs) may 
therefore improve treatment outcomes, particularly in the context of organ 
transplantation. The role of DAAs in transplantation is still under clinical investigation, 
yet carries the risk of recipient infection and HCV-induced disease, since DAAs act only 
after infection is established. Using entry inhibitors to block infection in transplanted 
individuals will likely improve patient outcomes during organ transplantation. This may 
also open perspectives for transplant of organs from HCV-positive donors to HCV-
negative recipients to alleviate the medical burden of organ shortage.  
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Approximately 150 million people are chronically infected with hepatitis C virus (HCV) 
worldwide. Due to the asymptomatic nature of the disease, many chronically infected 
individuals develop severe liver disease, including fibrosis, cirrhosis and hepatocellular 
carcinoma (HCC), in the absence of treatment. As there is currently limited screening and 
access to treatment,1 HCV-associated disease burden will likely remain considerable, 
even in the era of effective direct-acting antivirals.2 Currently, HCV-induced end-stage 
liver disease is the leading indication for liver transplantation (LT).3 In the United States, 
for example, approximately 40% of LT is due to liver failure associated with HCV 
infection. However, transplant of an HCV-negative donor liver into an HCV-positive 
recipient universally leads to graft reinfection in the absence of treatment. Allograft 
failure due to reinfection is the most common cause for retransplantation and death 
among HCV-infected LT recipients.  
Despite the remarkable cure rates achieved by state-of-the-art direct-acting 
antivirals (DAAs), their ability to prevent liver graft reinfection still remains to be fully 
determined.3–5 For example, 35% of patients experienced liver graft reinfection even 
when treated with sofosbuvir and ribavirin during LT.6 Although DAA-based treatment 
regimens appear to be effective for some patients undergoing transplant, the high costs of 
even a single course of DAA therapy pose a barrier to widespread use.7 Current DAAs 
act after infection is already established, when virus-induced disease and drug-related 
adverse effects pose potential risks for the patient, especially in the context of LT where 
patients undergoing transplant are immunosuppressed and may present with co-
morbidities. Furthermore, HCC risk persists even following viral cure, and enhanced 
HCC recurrence associated with use of DAA in several cohorts is under investigation.8 
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Finally, although drug resistance in DAA combination therapies is limited to a small 
fraction of patients, it can still arise, and some patient groups may pose particular 
challenges.9 Overall, the current strategy of DAA treatment following LT, while 
successful in the large majority of treated patients, does pose a number of risks. 
In general, a major challenge facing transplantation is organ shortage. In the 
United States, there are currently approximately 120,000 patients on waiting lists for 
organ transplant, yet only approximately 30,000 transplants are performed annually.10 
The most acute need is for kidneys, where the median wait time for a kidney transplant is 
4.5 years,11 and 13 people are estimated to die each day waiting for a kidney transplant.10 
Organ shortage could be alleviated by transplanting organs from HCV-positive patients 
into HCV-negative recipients, which no longer poses a significant contraindication.12–14 
Shorter waitlist times where HCV-positive organs are accepted lead to improved 
transplant outcomes.15 Nonetheless, transplant recipients receiving organs from HCV-
positive donors are at risk of acquiring HCV infection following transplantation. In an 
early study before DAA therapy was available, 50% of recipients of organs (kidney, heart 
and liver) transplanted from HCV-positive donors became HCV-positive.16 Even with 
DAA treatment, transplantation of organs from HCV-positive individuals to HCV-
negative recipients is often associated with less positive outcomes,12 which is likely 
attributed to de novo HCV infection of the recipient. Furthermore, the high costs 
associated with DAA therapy warrant the pursuit of more cost-effective measures.7 Novel 
strategies to address these limitations could increase the pool of donor organs available, 
improve transplant outcomes and reduce costs to further alleviate the medical burden of 
organ shortage. 
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One such strategy is to block de novo infection altogether by using HCV entry 
inhibitors. In the case of LT for individuals with HCV-induced end-stage liver disease, 
this would protect the transplanted liver from both infection and potential virus-induced 
complications. Notably, this is the standard of care in LT for hepatitis B virus (HBV) 
infection,17 where it is critical to block the establishment of HBV reservoirs in the host 
cell nucleus (i.e., persistent covalently-closed circular DNA or viral integration). 
Although HCV does not establish persistence by these mechanisms, similar approaches to 
prevent infection of transplanted organs should be considered for HCV. This would allow 
HCV-positive patients to receive liver transplants from HCV-negative donors without the 
risk of graft reinfection. Similarly, for HCV-negative recipients receiving organs from 
HCV-positive donors, entry inhibitors could be used to protect the recipient from HCV 
infection and potential virus-induced disease, and avoid costs associated with DAA 
therapy.  
HCV entry is a multi-step process that involves several cellular factors and as 
such provides a number of antiviral targets. Following initial attachment of virions to 
cellular glycosaminoglycans18 and lipoprotein receptors,19 interaction with the scavenger 
receptor class B type I (SR-BI)20 is thought to prime the viral particle for binding to 
CD81.21 CD81 engagement regulates viral entry by activating signalling pathways such 
as the epidermal growth factor receptor (EGFR) cascade.22 Association of CD81 with the 
tight junction protein claudin-1 (CLDN1)23 is required for the internalization of the HCV 
particle into clathrin-containing endosomes, allowing for low pH-induced fusion. Other 
factors, such as the Niemann-Pick C1-like 1 (NPC1L1) cholesterol absorption receptor,24 
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also contribute to HCV entry, although the specific mechanisms involved and their in 
vivo roles have not been fully elucidated.  
A number of inhibitors interfering with HCV entry are in preclinical and clinical 
development.25 Entry inhibitors offer a number of attractive features. By acting through 
complementary mechanisms of action, they may synergize with clinically approved 
DAAs to reduce the duration and cost of treatment.9 Furthermore, they block viral 
replication at a step before persistent reservoirs can be established. Blocking viral entry 
may also allow cure of chronic HCV infection, as virus-infected hepatocytes are 
eliminated by hepatocyte turnover in the absence of de novo infection.26 Entry inhibitors 
target either viral or cellular factors. Monoclonal antibodies or small molecules targeting 
virion glycoproteins typically interfere with viral attachment to cellular host factors, or 
block conformational changes in virion glycoproteins required for fusion.25 However, 
antivirals targeting non-virally encoded features are expected to have a higher genetic 
barrier to resistance. Molecules targeting HCV envelope lipids (derived from host cell 
membranes) modulate membrane fluidity or curvature to block fusion of viral and 
cellular membranes show great promise in preclinical models.25 However, antiviral 
approaches targeting host proteins are the furthest along in development.  
CD81, SRBI and CLDN1 are particularly relevant host targets, considering their 
well-defined and crucial roles in HCV entry. Indeed, monoclonal antibodies directed 
against CD81,27 SR-BI,28 and CLDN126, 29 protect human liver chimeric mice from HCV 
infection by interfering with the HCV entry process. A small molecule inhibitor of SR-BI 
termed ITX5061 inhibits HCV entry at a post-binding step and was evaluated in a phase 
1b clinical trial in liver transplant recipients with HCV infection (NCT01560468). 
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ITX5061 was safe and well tolerated,30 and reduced plasma HCV RNA following 
transplant.31 Other entry inhibitors in clinical evaluation for HCV infection are also small 
molecules, in this case targeting EGFR (erlotinib; clinical trial NCT01835938) and 
NPC1L1 (ezetimibe; clinical trial NCT02126137). 
Polyclonal immune globulins targeting HCV (analogous to the HBV immune 
globulin in standard of care in the context of LT for HBV infection) broadly protect 
against HCV infection in cell culture32 and are effective in human liver chimeric mice.33 
The polyclonal immune globulin Civacir is under evaluation in a phase 3 clinical trial for 
prevention of graft reinfection (NCT01804829). Broadly neutralizing monoclonal 
antibodies targeting the HCV envelope block viral entry to prevent and cure infection in 
cell culture and human liver chimeric mice have also been identified.34, 35 Interestingly, 
one such antibody combined with a single DAA effectively reduced HCV recurrence 
post-transplant in an exploratory efficacy trial for patients with active HCV infection at 
time of transplantation.36 This study provides proof of concept for inclusion of entry 
inhibitors in combination therapy approaches to prevent HCV infection during 
transplantation. 
DAAs have revolutionized HCV treatment, and by doing so have enabled major 
advances in organ transplantation in HCV-infected individuals. Furthermore, they have 
opened perspectives to alleviate organ shortage by enabling transplant of organs from 
HCV-positive individuals to HCV-negative recipients. However, the potential risks of 
DAA failure9 and HCV-induced liver disease,8 including the severe variant of fibrosing 
cholestatic hepatitis, as well as the high costs associated with DAAs,7 warrant the 
investigation of novel complementary approaches to prevent infection in transplanted 
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individuals, rather than relying on treatment of patients after infection is established. 
HCV entry inhibitors, some of which have shown promise in clinical trials, are poised to 
augment current therapeutic approaches to improve organ transplantation outcomes 
where HCV infection is possible. If short-term administration of entry inhibitors peri-
transplantation during the hospital stay can efficiently prevent HCV infection, entry 
inhibitors may not only improve patient outcomes but also simplify management and 
potentially reduce costs of antiviral therapy. The optimal deployment of such a 
prophylactic strategy will depend on several important factors, including cost, safety, and 
convenience. Further evaluation of a variety of prophylactic approaches appears 
warranted, particularly as transplant centres begin exploring empiric DAA prophylaxis. 
An ounce of prevention may indeed be worth a pound of cure for HCV infection during 
transplantation. 
 
 
 
 
 
 
 
 
 
 
 
	 10	
References: 
1. Edlin, B. R. (2016) Access to treatment for hepatitis C virus infection: time to put 
patients first. Lancet Infect Dis 16, e196-201. 
2. Chhatwal, J., Wang, X., Ayer, T., Kabiri, M., Chung, R. T., Hur, C., Donohue, J. 
M., Roberts, M. S., and Kanwal, F. (2016) Hepatitis C Disease Burden in the United 
States in the era of oral direct-acting antivirals. Hepatology 64, 1442-1450. 
3. Felmlee, D. J., Coilly, A., Chung, R. T., Samuel, D., and Baumert, T. F. (2016) 
New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect 
Dis 16, 735-745. 
4. Chung, R. T., and Baumert, T. F. (2014) Curing chronic hepatitis C--the arc of a 
medical triumph. N Engl J Med 370, 1576-1578. 
5. Price, J. C., and Terrault, N. A. (2015) Treatment of hepatitis C in liver transplant 
patients: interferon out, direct antiviral combos in. Liver Transpl 21, 423-434. 
6. Curry, M. P., Forns, X., Chung, R. T., Terrault, N. A., Brown, R., Fenkel, J. M., 
Gordon, F., O’Leary, J., Kuo, A., Schiano, T., Everson, G., Schiff, E., Befeler, A., 
Gane, E., Saab, S., McHutchison, J. G., Subramanian, G. M., Symonds, W. T., 
Denning, J., McNair, L., Arterburn, S., Svarovskaia, E., Moonka, D., and Afdhal, 
N. (2015) Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver 
transplantation: an open-label study. Gastroenterology 148, 100-107.e1. 
7. Cortesi, P. A., Mantovani, L. G., Ciaccio, A., Rota, M., Mazzarelli, C., Cesana, G., 
Strazzabosco, M., and Belli, L. S. (2015) Cost-Effectiveness of New Direct-Acting 
Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis. Am J Transplant 
15, 1817-1826. 
	 11	
8. Baumert, T. F., Jühling, F., Ono, A., and Hoshida, Y. (2017) Hepatitis C-related 
hepatocellular carcinoma in the era of new generation antivirals. BMC Med 15, 52. 
9. Colpitts, C. C., and Baumert, T. F. (2016) Addressing the Challenges of Hepatitis C 
Virus Resistance and Treatment Failure. Viruses 8,  
10. Data, O. P. A. T. (2017)  
11. Reese, P. P., Harhay, M. N., Abt, P. L., Levine, M. H., and Halpern, S. D. (2016) 
New Solutions to Reduce Discard of Kidneys Donated for Transplantation., J Am 
Soc Nephrol 27, 973-980. 
12. Englum, B. R., Ganapathi, A. M., Speicher, P. J., Gulack, B. C., Snyder, L. D., 
Davis, R. D., and Hartwig, M. G. (2016) Impact of donor and recipient hepatitis C 
status in lung transplantation., J Heart Lung Transplant 35, 228-235. 
13. Goldberg, D. S., Abt, P. L., Blumberg, E. A., Van Deerlin, V. M., Levine, M., 
Reddy, K. R., Bloom, R. D., Nazarian, S. M., Sawinski, D., Porrett, P., Naji, A., 
Hasz, R., Suplee, L., Trofe-Clark, J., Sicilia, A., McCauley, M., Farooqi, M., 
Gentile, C., Smith, J., and Reese, P. P. (2017) Trial of Transplantation of HCV-
Infected Kidneys into Uninfected Recipients., N Engl J Med 376, 2394-2395. 
14. Levitsky, J., Formica, R. N., and Bloom…, R. D. (2017) The American Society of 
transplantation consensus conference on the use of hepatitis C viremic donors in 
solid organ transplantation, American Journal of …  
15. Scalea, J. R., Barth, R. N., Munivenkatappa, R., Philosophe, B., Cooper, M., 
Whitlow, V., and LaMattina, J. C. (2015) Shorter waitlist times and improved graft 
survivals are observed in patients who accept hepatitis C virus+ renal allografts., 
Transplantation 99, 1192-1196. 
	 12	
16. Pereira, B. J., Milford, E. L., Kirkman, R. L., and Levey, A. S. (1991) Transmission 
of hepatitis C virus by organ transplantation., N Engl J Med 325, 454-460. 
17. Perrillo, R., Buti, M., Durand, F., Charlton, M., Gadano, A., Cantisani, G., Loong, 
C. C., Brown, K., Hu, W., Lopez-Talavera, J. C., and Llamoso, C. (2013) Entecavir 
and hepatitis B immune globulin in patients undergoing liver transplantation for 
chronic hepatitis B., Liver Transpl 19, 887-895. 
18. Xu, Y., Martinez, P., Séron, K., Luo, G., Allain, F., Dubuisson, J., and Belouzard, 
S. (2015) Characterization of hepatitis C virus interaction with heparan sulfate 
proteoglycans., J Virol 89, 3846-3858. 
19. Yamamoto, S., Fukuhara, T., Ono, C., Uemura, K., Kawachi, Y., Shiokawa, M., 
Mori, H., Wada, M., Shima, R., Okamoto, T., Hiraga, N., Suzuki, R., Chayama, K., 
Wakita, T., and Matsuura, Y. (2016) Lipoprotein Receptors Redundantly Participate 
in Entry of Hepatitis C Virus., PLoS Pathog 12, e1005610. 
20. Scarselli, E., Ansuini, H., Cerino, R., Roccasecca, R. M., Acali, S., Filocamo, G., 
Traboni, C., Nicosia, A., Cortese, R., and Vitelli, A. (2002) The human scavenger 
receptor class B type I is a novel candidate receptor for the hepatitis C virus., 
EMBO J 21, 5017-5025. 
21. Pileri, P., Uematsu, Y., Campagnoli, S., Galli, G., Falugi, F., Petracca, R., Weiner, 
A. J., Houghton, M., Rosa, D., Grandi, G., and Abrignani, S. (1998) Binding of 
hepatitis C virus to CD81., Science 282, 938-941. 
22. Lupberger, J., Zeisel, M. B., Xiao, F., Thumann, C., Fofana, I., Zona, L., Davis, C., 
Mee, C. J., Turek, M., Gorke, S., Royer, C., Fischer, B., Zahid, M. N., Lavillette, 
D., Fresquet, J., Cosset, F. L., Rothenberg, S. M., Pietschmann, T., Patel, A. H., 
	 13	
Pessaux, P., Doffoël, M., Raffelsberger, W., Poch, O., McKeating, J. A., Brino, L., 
and Baumert, T. F. (2011) EGFR and EphA2 are host factors for hepatitis C virus 
entry and possible targets for antiviral therapy., Nat Med 17, 589-595. 
23. Evans, M. J., von Hahn, T., Tscherne, D. M., Syder, A. J., Panis, M., Wölk, B., 
Hatziioannou, T., McKeating, J. A., Bieniasz, P. D., and Rice, C. M. (2007) 
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry., Nature 
446, 801-805. 
24. Sainz, B., Barretto, N., Martin, D. N., Hiraga, N., Imamura, M., Hussain, S., Marsh, 
K. A., Yu, X., Chayama, K., Alrefai, W. A., and Uprichard, S. L. (2012) 
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a 
new hepatitis C virus entry factor., Nat Med 18, 281-285. 
25. Colpitts, C. C., Verrier, E. R., and Baumert, T. F. (2015) Targeting Viral Entry for 
Treatment of Hepatitis B and C Virus Infections., ACS Infect Dis 1, 420-427. 
26. Mailly, L., Xiao, F., Lupberger, J., Wilson, G. K., Aubert, P., Duong, F. H., 
Calabrese, D., Leboeuf, C., Fofana, I., Thumann, C., Bandiera, S., Lütgehetmann, 
M., Volz, T., Davis, C., Harris, H. J., Mee, C. J., Girardi, E., Chane-Woon-Ming, 
B., Ericsson, M., Fletcher, N., Bartenschlager, R., Pessaux, P., Vercauteren, K., 
Meuleman, P., Villa, P., Kaderali, L., Pfeffer, S., Heim, M. H., Neunlist, M., Zeisel, 
M. B., Dandri, M., McKeating, J. A., Robinet, E., and Baumert, T. F. (2015) 
Clearance of persistent hepatitis C virus infection in humanized mice using a 
claudin-1-targeting monoclonal antibody., Nat Biotechnol 33, 549-554. 
27. Meuleman, P., Hesselgesser, J., Paulson, M., Vanwolleghem, T., Desombere, I., 
Reiser, H., and Leroux-Roels, G. (2008) Anti-CD81 antibodies can prevent a 
	 14	
hepatitis C virus infection in vivo., Hepatology 48, 1761-1768. 
28. Meuleman, P., Catanese, M. T., Verhoye, L., Desombere, I., Farhoudi, A., Jones, C. 
T., Sheahan, T., Grzyb, K., Cortese, R., Rice, C. M., Leroux-Roels, G., and Nicosia, 
A. (2012) A human monoclonal antibody targeting scavenger receptor class B type 
I precludes hepatitis C virus infection and viral spread in vitro and in vivo., 
Hepatology 55, 364-372. 
29. Colpitts, C. C., Tawar, R. G., Mailly, L., Thumann, C., Heydmann, L., Durand, S. 
C., Xiao, F., Robinet, E., Pessaux, P., Zeisel, M. B., and Baumert, T. F. (2017) 
Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention 
and cure of HCV infection without escape., Gut  
30. Sulkowski, M. S., Kang, M., Matining, R., Wyles, D., Johnson, V. A., Morse, G. 
D., Amorosa, V., Bhattacharya, D., Coughlin, K., Wong-Staal, F., Glesby, M. J., 
and AIDS, C. T. G. A. P. T. (2014) Safety and antiviral activity of the HCV entry 
inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-
blind, phase 1b study., J Infect Dis 209, 658-667. 
31. Rowe, I. A., Tully, D. C., Armstrong, M. J., Parker, R., Guo, K., Barton, D., Morse, 
G. D., Venuto, C. S., Ogilvie, C. B., Hedegaard, D. L., McKelvy, J. F., Wong-Staal, 
F., Allen, T. M., Balfe, P., McKeating, J. A., and Mutimer, D. J. (2016) Effect of 
scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C 
virus infection undergoing liver transplantation., Liver Transpl 22, 287-297. 
32. Tawar, R. G., Heydmann, L., Bach, C., Schüttrumpf, J., Chavan, S., King, B. J., 
McClure, C. P., Ball, J. K., Pessaux, P., Habersetzer, F., Bartenschlager, R., Zeisel, 
M. B., and Baumert, T. F. (2016) Broad neutralization of hepatitis C virus-resistant 
	 15	
variants by Civacir hepatitis C immunoglobulin., Hepatology 64, 1495-1506. 
33. Meuleman, P., Bukh, J., Verhoye, L., Farhoudi, A., Vanwolleghem, T., Wang, R. 
Y., Desombere, I., Alter, H., Purcell, R. H., and Leroux-Roels, G. (2011) In vivo 
evaluation of the cross-genotype neutralizing activity of polyclonal antibodies 
against hepatitis C virus., Hepatology 53, 755-762. 
34. de Jong, Y. P., Dorner, M., Mommersteeg, M. C., Xiao, J. W., Balazs, A. B., 
Robbins, J. B., Winer, B. Y., Gerges, S., Vega, K., Labitt, R. N., Donovan, B. M., 
Giang, E., Krishnan, A., Chiriboga, L., Charlton, M. R., Burton, D. R., Baltimore, 
D., Law, M., Rice, C. M., and Ploss, A. (2014) Broadly neutralizing antibodies 
abrogate established hepatitis C virus infection., Sci Transl Med 6, 254ra129. 
35. Keck, Z. Y., Wang, Y., Lau, P., Lund, G., Rangarajan, S., Fauvelle, C., Liao, G. C., 
Holtsberg, F. W., Warfield, K. L., Aman, M. J., Pierce, B. G., Fuerst, T. R., Bailey, 
J. R., Baumert, T. F., Mariuzza, R. A., Kneteman, N. M., and Foung, S. K. (2016) 
Affinity maturation of a broadly neutralizing human monoclonal antibody that 
prevents acute hepatitis C virus infection in mice., Hepatology 64, 1922-1933. 
36. Smith, H. L., Chung, R. T., Mantry, P., Chapman, W., Curry, M. P., Schiano, T. D., 
Boucher, E., Cheslock, P., Wang, Y., and Molrine, D. C. (2017) Prevention of 
allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-
HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept 
study., J Viral Hepat 24, 197-206. 
 
 
 
	 16	
 	
